Compare Micron Technology, Inc. (MU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs TransMedics Group Inc — how do they compare? Micron Technology, Inc. trades at $1,029 (market cap $1.17T), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Micron Technology, Inc. is far larger — about 427× TransMedics Group Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and TransMedics Group Inc for 24 Days on average.
| MU | TMDX | |
|---|---|---|
Market Cap | $1.17T | $2.74B |
Volume | 29,425,906 | 949,331 |
Sector | Technology | Health |
52-Week High | $1.21K | $150.42 |
52-Week Low | $181.60 | $61.99 |
Typical Hold Time | 48 Days | 24 Days |
Enterprise Value | $1.13T | $3.13B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,035.84, down 4.79% today, but maintains strong bullish momentum with 500% gains over the past year. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $33.42 versus $31.77, and maintains impressive profitability with 63.8% net income margin. Technical indicators remain bullish overall despite recent pullback, with support at $1,020 and resistance at $1,064. The company's strategic customer agreements covering 35% of revenue through 2030 provide visibility into future growth.
Micron presents compelling investment potential driven by AI memory demand surge and strong financial performance, though risks include cyclical industry exposure and potential growth deceleration. Analyst consensus remains strongly bullish with 82.9% buy ratings and $1,590 price target, representing 53% upside. The stock's valuation at 13.94 P/E appears reasonable given projected revenue growth to $133.2B in 2026.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
